Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125056993 | 12505699 | 3 | F | 20160406 | 20160825 | 20160628 | 20160907 | EXP | GB-MHRA-ADR 23481241 | GB-TEVA-669344ACC | TEVA | 67.00 | YR | F | Y | 80.00000 | KG | 20160907 | MD | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125056993 | 12505699 | 1 | PS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | U | U | 74124 | ||||||||||
125056993 | 12505699 | 2 | SS | CLEXANE | ENOXAPARIN SODIUM | 1 | Subcutaneous | Y | U | 5SK16 | 0 | 120 | MG | SOLUTION FOR INJECTION | QD | ||||
125056993 | 12505699 | 3 | C | ADCAL-D3 | CALCIUM CARBONATECHOLECALCIFEROL | 1 | 0 | ||||||||||||
125056993 | 12505699 | 4 | C | LETROZOLE. | LETROZOLE | 1 | 0 | ||||||||||||
125056993 | 12505699 | 5 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
125056993 | 12505699 | 6 | C | ZOMORPH | MORPHINE SULFATE | 1 | 0 | ||||||||||||
125056993 | 12505699 | 7 | C | PERJETA | PERTUZUMAB | 1 | 0 | ||||||||||||
125056993 | 12505699 | 8 | C | HERCEPTIN | TRASTUZUMAB | 1 | ONGOING | 0 | 1 | DF | Q3W | ||||||||
125056993 | 12505699 | 9 | C | PERTUZUMAB | PERTUZUMAB | 1 | ONGOING | 0 | 1 | DF | Q3W | ||||||||
125056993 | 12505699 | 10 | C | DENOSUMAB | DENOSUMAB | 1 | 0 | 1 | DF | INJECTION | |||||||||
125056993 | 12505699 | 11 | C | DOCETAXEL. | DOCETAXEL | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125056993 | 12505699 | 1 | Antibiotic therapy |
125056993 | 12505699 | 2 | Peripheral embolism |
125056993 | 12505699 | 8 | Breast cancer stage IV |
125056993 | 12505699 | 9 | Breast cancer stage IV |
125056993 | 12505699 | 10 | Bone disorder |
125056993 | 12505699 | 11 | Breast cancer stage IV |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125056993 | 12505699 | HO |
125056993 | 12505699 | LT |
125056993 | 12505699 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125056993 | 12505699 | Blister | |
125056993 | 12505699 | Burning sensation | |
125056993 | 12505699 | Dermatitis | |
125056993 | 12505699 | Erythema multiforme | |
125056993 | 12505699 | Pain | |
125056993 | 12505699 | Protein deficiency | |
125056993 | 12505699 | Rash erythematous | |
125056993 | 12505699 | Scab | |
125056993 | 12505699 | Skin erosion | |
125056993 | 12505699 | Skin haemorrhage | |
125056993 | 12505699 | Tachycardia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125056993 | 12505699 | 2 | 20160317 | 20160417 | 0 | |
125056993 | 12505699 | 3 | 20151016 | 0 | ||
125056993 | 12505699 | 11 | 20160210 | 0 |